Brief: Peptidream Inc: Received $7.5 Million Milestone Fee From Novartis AG Based On Peptide Drug Conjugate Development Contract
16/10/2023 07:33
Oct 16 (Reuters) - PeptiDream Inc 4587.T :
* PEPTIDREAM INC - RECEIVED $7.5 MILLION MILESTONE FEE FROM
NOVARTIS AG BASED ON PEPTIDE DRUG CONJUGATE DEVELOPMENT CONTRACT
Source text for Eikon: ID:nTSvp8a8eb
Further company coverage: 4587.T
(Reporting by Kantaro Komiya)
((Kantaro.Komiya@thomsonreuters.com;))
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner